<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01695005</url>
  </required_header>
  <id_info>
    <org_study_id>14547</org_study_id>
    <secondary_id>I6F-MC-JJCA</secondary_id>
    <nct_id>NCT01695005</nct_id>
  </id_info>
  <brief_title>A Study of LY3039478 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find a recommended dose level of LY3039478 that can safely be
      taken by participants with advanced cancer or cancer that has spread to other parts of the
      body, including but not limited to lymphoma. The study will also explore changes to various
      markers in blood cells and tissue. Finally, the study will help to document any tumor
      activity this drug may have.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A of this study, participants with advanced/metastatic cancer (including lymphoma)
      will receive increasing doses of LY3039478 to define the dose level for Part B, C, D and E.
      In Part B, C, D and E LY3039478 will be explored at a predefined fixed dose level.
      Participants in Part B and D must have a defined alteration in a certain molecular pathway.
      Enrollment of participants in Part B, C, D and E will start once Part A is completed. In Part
      F participants will receive increasing doses of LY3039478 in combination with prednisone to
      define the maximum tolerated dose level.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and F: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline to disease progression or participant discontinuation (estimated 8 -12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B, C, D, E and F: Number of Participants with Tumor Response</measure>
    <time_frame>Baseline to disease progression or participant discontinuation (estimated 8 -12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3039478</measure>
    <time_frame>Predose up to 30 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3039478</measure>
    <time_frame>Predose up to 30 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants with Tumor Response</measure>
    <time_frame>Baseline to disease progression or participant discontinuation (estimated 8 -12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B, C, D, E and F: Duration of Response (DoR)</measure>
    <time_frame>Date of Complete Response or Partial Response to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B, C, D, E and F: Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death from Any Cause (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B, C, D, E and F: Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated up to 14 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>LY3039478 - Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3039478 - Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 LY3039478 + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 LY3039478 + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3039478</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478 - Dose Escalation</arm_group_label>
    <arm_group_label>LY3039478 - Cohort Expansion</arm_group_label>
    <arm_group_label>Dose 1 LY3039478 + Prednisone</arm_group_label>
    <arm_group_label>Dose 2 LY3039478 + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose 1 LY3039478 + Prednisone</arm_group_label>
    <arm_group_label>Dose 2 LY3039478 + Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all parts: The participant must be, in the judgment of the investigator, an
             appropriate candidate for experimental therapy after available standard therapies have
             failed to provide clinical benefit for their advanced or metastatic cancer.

          -  For Dose Escalation (Part A): The participant must have histological or cytological
             evidence of cancer, either a solid tumor or a lymphoma, which is advanced or
             metastatic.

          -  For Part B: All participants must have a histological evidence of their advanced or
             metastatic cancer and prescreened alterations in a defined pathway.

          -  For Part C: All participants must have histological evidence of advanced or metastatic
             specific subtypes of soft tissue sarcoma.

          -  For Part D: All participants must have histological evidence of advanced or metastatic
             cancer and prescreened alterations in a defined pathway.

          -  Cohort 1: Participants must have triple negative breast cancer.

          -  Cohort 2: Participants must have hepatocellular carcinoma (HCC). These participants
             should have Child-Pugh stage A.

          -  Cohort 3: Participants must have cholangiocarcinoma.

          -  Cohort 4: Participants must have chronic lymphocytic leukemia.

          -  Cohort 5: Participants must have a mature T cell, B cell, or natural killer (NK) cell
             neoplasm.

          -  For Part E: Participants must have adenoid cystic carcinoma (ACC).

          -  For Part F dose confirmation: Participants must have leiomyosarcoma and prescreened
             alterations in a defined pathway.

          -  As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the
             Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro
             Oncology (RANO) criteria for glioblastoma:

               -  For Dose Escalation (Part A): Have measurable or nonmeasurable disease.

               -  For Parts B, C, D, E and F: Have measurable disease or reliable biomarker
                  measure.

          -  For Parts B, C, D, E and F: Have available tumor tissue.

          -  Have adequate organ function.

          -  Have a performance status of less than or equal to 1 on the Eastern Cooperative
             Oncology Group (ECOG) scale and life expectancy of more than 12 weeks.

        Exclusion Criteria:

          -  Have symptomatic or non stable central nervous system (CNS) malignancy.

          -  Females who are pregnant or lactating.

          -  Have active bacterial, fungal, and/or known viral infection.

          -  Have malabsorptive syndromes, enteropathies, gastroenteritis (acute or chronic), or
             diarrhea (acute or chronic).

          -  Participants with HCC that:

               -  Have known HCC with fibro-lamellar or mixed histology.

               -  Have presence of clinically relevant ascites.

               -  Have had a liver transplant.

               -  Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C
                  virus infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JJCA#?postal=</url>
    <description>Click here for more information about this study: A Study of LY3039478 in Participants with Advanced Cancer</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

